Prevention of chronic kidney disease: The next step forward!

被引:12
作者
de Jong, Paul E. [1 ]
Gansevoort, Ron T. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Med, Div Nephrol, NL-9700 RB Groningen, Netherlands
关键词
albuminuria; chronic kidney disease; PREVEND; prevention; progressive renal failure;
D O I
10.1111/j.1440-1797.2006.00575.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The incidence of end stage renal disease in patients who have not experienced a classic primary renal disease is dramatically increasing. Chronic kidney disease (CKD) in these patients is due to diabetes, mostly type 2, hypertension and generalised atherosclerosis. As these patients are frequently diagnosed as having renal function impairment only in the late phase, more effort should be undertaken to diagnose them earlier, that is, at a time when renoprotective measures can still be undertaken. For that purpose, measurement of the estimated glomerular filtration rate (GFR) might be helpful. To properly interpret those measurements, however, we need to be aware of the pros and cons of the use of formulas to estimate the GFR. Most likely, a better way to detect subjects at risk of CKD in the early phase is screening by dipstick proteinuria or preferably by testing for (micro-) albuminuria. Because microalbuminuria not only indicates increased renal but also enhanced cardiovascular risk, the benefits of such screening programmes may have a much greater affect than only preventing renal disease.
引用
收藏
页码:240 / 244
页数:5
相关论文
共 39 条
[1]  
[Anonymous], 2000, J AM SOC NEPHROL
[2]  
[Anonymous], DIABETES CARE, DOI DOI 10.2337/DIACARE.25.2007.S85
[3]   Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria [J].
Asselbergs, FW ;
Diercks, GFH ;
Hillege, HL ;
van Boven, AJ ;
Janssen, WMT ;
Voors, AA ;
de Zeeuw, D ;
de Jong, PE ;
van Veldhuisen, DJ ;
van Gilst, WH .
CIRCULATION, 2004, 110 (18) :2809-2816
[4]   Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of REnal and vascular ENdstage disease (PREVEND) study and the prevention of REnal and vascular ENdstage disease intervention trial (PREVEND IT) [J].
Atthobari, J ;
Asselbergs, FW ;
Boersma, C ;
de Vries, R ;
Hillege, HL ;
van Gilst, WH ;
Gansevoort, RT ;
de Jong, PE ;
de Jong-van den Berg, LTW ;
Postma, MJ .
CLINICAL THERAPEUTICS, 2006, 28 (03) :432-444
[5]   Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction Of type 2 diabetes [J].
Brantsma, AH ;
Bakker, SJL ;
Hillege, HL ;
De Zeeuw, D ;
De Jong, PE ;
Gansevoort, RT .
DIABETES CARE, 2005, 28 (10) :2525-2530
[6]  
BRANTSMA AH, 2005, J AM SOC NEPHROL, V16, pA70
[7]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[8]   Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension [J].
Cerasola, G ;
Cottone, S ;
Mule, G ;
Nardi, E ;
Mangano, MT ;
Andronico, G ;
Contorno, A ;
LiVecchi, M ;
Galione, P ;
Renda, F ;
Piazza, G ;
Volpe, V ;
Lisi, A ;
Ferrara, L ;
Panepinto, N ;
Riccobene, R .
JOURNAL OF HYPERTENSION, 1996, 14 (07) :915-920
[9]   The metabolic syndrome and chronic kidney disease in US adults [J].
Chen, J ;
Muntner, P ;
Hamm, LL ;
Jones, DW ;
Batuman, V ;
Fonseca, V ;
Whelton, PK ;
He, J .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (03) :167-174
[10]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41